Skip to main content
. 2020 Jul 20;12(7):1969. doi: 10.3390/cancers12071969

Figure 1.

Figure 1

NKG2DIL7-chimeric antigen receptor (CAR T cells display enhanced antitumor activity in vitro. (a) Domain architecture of engineered NKG2D-CAR and NKG2DIL7-CAR constructs. (b) Cytotoxic activity of NKG2D-CAR or non-transduced T cells against prostate cancer cell lines was determined by Annexin-V staining. B16-F10 melanoma cells served as negative target cell control. The effector cells were co-cultured for 4 h with target cells at E:T ratio of 1:3, 1:1 and 3:1, respectively. (c,d) Cytotoxic assays were determined by Annexin-V staining at 16 h of co-culture of NKG2D-CAR or NKG2DIL7-CAR T with PC-3 at E:T ratios of 3:1,1:1 and 1:3. E (c), PC-3 tumor cell viability assay was performed after 72 h of co-culture with non-transducted T (NT), NKG2D-CAR or NKG2DIL7-CAR T cells at E:T ratio of 3:1 (d). (e,f) Flow cytometric analysis of CD69 and granzyme B in T cells after the stimulation of tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data are representative of greater than three independent experiments.